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Abstract: The aim of this study is to evaluate the feasibility and safety of random-start 
controlled ovarian hyperstimulation (COH) for emergency fertility preservation, regardless of 
the phase of the menstrual cycle. A self-controlled pilot clinical trial (NCT01385332) was per-
formed in an acute-care teaching hospital and in two private reproductive centers in Barcelona, 
Spain. Eleven egg donors participated in the study. Two random-start gonadotropin-releasing 
hormone (GnRH) antagonist protocols were assessed in which ganirelix was initiated on either 
day 10 (protocol B) or on day 20 (protocol C) of the menstrual cycle and was continued until 
estradiol levels were below 60 pg/dL. These protocols were compared with a standard protocol 
(protocol A). The main outcome of interest was the number of metaphase 2 oocytes retrieved. 
Results from this study show that the number of mature oocytes retrieved was comparable 
across the different protocols (14.3±4.6 in the standard protocol versus 13.0±9.1 and 13.2±5.2 
in protocols B and C, respectively; values expressed as mean ± standard deviation). The mean 
number of days needed for a GnRH antagonist to lower estradiol levels, as well as the ongo-
ing pregnancy rates, were also similar when protocols B (stimulation in follicular phase) and 
C (stimulation on luteal phase) were compared with protocol A (standard stimulation). GnRH 
antagonists can be effectively used for random-start controlled ovarian hyperstimulation with 
an ovarian response similar to that of standard protocols, and the antagonists appear suitable 
for emergency fertility preservation in cancer patients.
Keywords: controlled ovarian hyperstimulation, GnRH antagonists, emergency fertility 
preservation, cancer patients
Introduction
Reproductive-age women who are diagnosed with a malignant disease face the poten-
tial risk of losing their fertility because of chemotherapy or radiation therapy and, 
therefore, they risk losing the opportunity to have children.1 In 2009, the American 
Cancer Society predicted more than 190,000 new cases of breast cancer in women.2 
They estimated that roughly 18,600 of these women would be younger than 45 years of 
age.2 In a study of 82,699 incident cases of breast cancer diagnosed in Spain during the 
period from 1980–2004, breast cancer increased annually by 1.7% during that period 
for women younger than 45 years of age.3 Also, in a survey of 657 young women with 
a history of early-stage breast cancer, 57% recalled having substantial concerns at the 
time of diagnosis about becoming infertile with treatment.4
The best approach and treatment options for cancer patients who are concerned 
about preserving and managing their fertility are still matters of debate, albeit fertility 
preservation approaches should be considered as early as possible during treatment 





planning.5 For women whose cancer treatment cannot be 
delayed, there is a narrow window of opportunity for egg 
harvesting.6 Vitrification of oocytes is an efficient method 
for oocyte cryopreservation, although previous controlled 
ovarian stimulation is necessary.7 The conventional approach 
requires approximately 2 weeks of ovulation induction from 
the beginning of the menstrual cycle; this process could 
entail a delay by up to 6 weeks for starting cancer treatment, 
depending on the phase of the menstrual cycle during which 
the patient is referred.6
The use of gonadotropin-releasing hormone (GnRH) 
antagonists has emerged as a convenient strategy to reduce the 
duration of the treatment cycle.8–11 However, there is limited 
evidence regarding the feasibility of GnRH antagonist proto-
cols to initiate controlled ovarian hyperstimulation (COH) at a 
random date in the menstrual cycle. Random-start COH could 
be a valuable approach for emergency fertility preservation 
in cancer patients. Therefore, a self-controlled, exploratory 
pilot clinical trial was designed to assess whether the use of 
GnRH antagonists to initiate COH at a random day of the 
menstrual cycle would allow the retrieval of the same number 
of mature oocytes as a standard long protocol would.
Materials and methods
Design and study population
This self-controlled clinical trial was conducted on egg 
donors recruited consecutively at an acute-care teaching 
hospital and at two private reproductive medicine centers 
in Barcelona, Spain between January 2011 and December 
2011. The purpose of this study was to determine the effi-
cacy and safety of two new protocols for COH, defined as 
the total number of retrieved oocytes. Although this study 
was performed on egg donors, these new protocols are 
intended to be implemented on fertility preservation patients. 
All participants gave written informed consent for ovarian 
stimulation and egg donation. In addition, all recipients who 
received embryos obtained from these protocols also gave 
written informed consent. The study protocol was approved 
by the Ethics Committee for Clinical Research of Parc de 
Salut Mar, Barcelona, Spain. The study was registered with 
ClinicalTrials.gov on May 28, 2010 (NCT01385332).
Women enrolled in the study were between 18 and 
32 years of age and had no previous history of chemo-
therapy, exposure to any gonadotoxic drugs (for example, 
methotrexate), a history of ovarian surgery, nor  infertility. 
Other inclusion criteria comprehended a body mass 
index (BMI) between 12 kg/m2 and 28 kg/m2, and base-
line  follicle-stimulating hormone (FSH) levels below 
10 mIU/mL. Patients included were negative for hepatitis C 
virus, hepatitis B virus, human immunodeficiency virus, 
and syphilis infection. In addition, women with polycystic 
ovarian syndrome and gonadotropin allergies were excluded 
from this study. Male factor, defined by the World Health 
Organization criteria, was also considered an exclusion 
criterion.12
All participants were scheduled in the early follicular 
phase (days 3–5 of the menstrual cycle) for a baseline evalu-
ation in which serum levels of FSH, estradiol, and luteinizing 
hormone (LH) were measured. An antral follicle count (AFC) 
was performed using transvaginal ultrasonography on days 1 
or 2 of the menstrual cycle.
Ovarian stimulation cycles
All women underwent two COH cycles. First, the standard 
COH protocol was initiated during the early follicular 
phase (protocol A, control group). Then, following a self-
controlled, open-label design, patients underwent a second 
cycle of COH either in the midfollicular phase by start-
ing a GnRH antagonist on day 10 of the menstrual cycle 
(protocol B), or in the early luteal phase by starting a GnRH 
antagonist on day 20 of the menstrual cycle (protocol C). 
Prior to the first COH cycle, participants were randomly 
assigned to protocol B or C using a computer-generated 
table of random numbers.
Protocol A (control group)
Ovarian stimulation was initiated on day 2 of the menstrual 
cycle with 225 IU/day of recombinant FSH (rFSH) (Puregon®; 
Merck and Co, Inc., Whitehouse Station, NJ, USA) for 5 days. 
The dose of rFSH was adjusted for each patient according to 
the follicular growth detected by ultrasonography after the 5th 
day of rFSH administration. A GnRH antagonist (ganirelix; 
Orgalutran®; Merck and Co, Inc.) at a dose of 0.25 mg/dL 
per day was administered from day 6 of rFSH onwards to 
prevent LH surge. When at least three follicles at least 17 mm 
in diameter were observed by ultrasonography, a GnRH ago-
nist (Procrin®; Abbott Laboratories, Abbott Park, IL, USA) 
at a dose of 0.2 mL/IU was given as a trigger. Oocytes were 
retrieved transvaginally 36 hours later and fertilized either 
by conventional in vitro fertilization (IVF) or by means of 
intracytoplasmic sperm injection (ICSI).
Protocols B and C (intervention)
In protocols B and C, ganirelix treatment was initiated 
on day 10 (protocol B, midfollicular phase) or on day 20 
(protocol C, early luteal phase) of the menstrual cycle at 





a dose of 0.25 mg/dL per day. Ganirelix treatment was given 
until serum estradiol levels were below 60 pg/dL. Then, 
the standard protocol was started with 225 IU/day of rFSH 
(Puregon®; Merck and Co, Inc.). As in protocol A, the dose 
of rFSH was adjusted depending on the individual ovarian 
response after the 5th day of treatment. A fixed dose of 
ganirelix, 0.25 mg/dL per day, was administered from day 6 
of rFSH treatment onwards to prevent premature LH surges. 
When at least three follicles had reached at least 17 mm in 
diameter, 0.2 mL/IU of the GnRH agonist Procrin® (Abbott 
Laboratories) was administered to induce ovulation. Oocytes 
were retrieved transvaginally 36 hours later and fertilized 
either by conventional IVF or ICSI. The details of protocols B 
and C are shown in Figure 1.
Priming/transfer protocol
Recipients of donor eggs were downregulated with 3.75 mg of 
a GnRH agonist, Decapeptyl® (Ipsen Pharma, Paris, France), 
and endometrial priming was induced by a transdermal patch, 
Evopad® (Janssen Pharmaceutica NV, Beerse, Belgium), 
which released 75 µg/day of estradiol. Natural micronized 
progesterone (Utrogestan®; SEID S.A., Barcelona, Spain) at 
a dose of 800 mg/day was used as luteal supplementation. 
A single embryo was transferred on day 3.
Protocol B: from the 10th day of the menstrual cycle
Protocol C: from the 20th day of the menstrual cycle
When E2 <60 pg/mL:
Day 20: initiation
of GnRH antag
Day 6 of COH:
add GnRH antag
3 follicle >17 mm
Procrin 0.2 mL/UI
– Stop GnRH antag
– Initiate rFSH
When E2 <60 pg/mL:
– Stop GnRH antag
– Initiate rFSH
Day 6 of COH:
add GnRH antag
3 follicle >17 mm
Procrin 0.2 mL/UIDay 10: initiation
of GnRH antag
rFSH 225 UI/day
GnRH antag 0.25 mg/day sc
Stimulation day
Cycle day
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rFSH 225 UI/day
GnRH antag 0.25 mg/day sc
Stimulation day
Cycle day
Figure 1 Random-start GnRH antagonist protocols in the midfollicular phase (protocol B) versus the early luteal phase (protocol C).
Abbreviations: E2, estradiol; GnRH, gonadotropin-releasing hormone; antag, antagonist; sc, subcutaneous; rFSH, recombinant follicle-stimulating hormone; COH, controlled 
ovarian hyperstimulation.





14.3±4.6 in the standard protocol versus 13.0±9.1 and 
13.2±5.2 in protocols B and C, respectively, as shown in 
Table 2). In addition, no differences were observed in terms 
of the fertilization rate, the percentage of top-quality embryos 
achieved, or the mean number of frozen embryos when the 
standard protocol was compared with either the midfollicular 
phase protocol or the early luteal phase protocol, as shown 
in Table 2.
The mean ± SD number of days of GnRH antagonist 
treatment needed to decrease serum estradiol levels below 
60 pg/dL was 2.8±0.8 days in protocol B and 3.6±1.6 days in 
protocol C (Table 2). In addition, patients were on ganirelix 
during more days for protocols B and C than for the standard 
protocol (Protocol B: 5.8±1.9 versus 7.8±3.3 in the midfol-
licular arm; and Protocol C: 6.5±0.6 versus 8.2±3.5 in the 
early luteal arm; although the differences were not statisti-
cally significant). The mean numbers of days of stimulation 
were also similar for both GnRH antagonist protocols B and 
C and for the standard COH protocol (Table 2). Additionally, 
the ongoing pregnancy rates for egg recipients were also 
similar in both arms when comparing protocols B or C with 
Outcome measures
The number of mature oocytes, defined as the number of 
metaphase 2 oocytes retrieved, was the main outcome of 
interest. Participants were followed for 1–3 hours after fol-
licular aspiration. Fertilized embryos were classified on day 3 
in accordance with the Spanish Association of Reproductive 
Biology (ASEBIR) embryo assessment criteria (ASEBIR, 
2008). Egg recipients were followed until the 12th week of 
pregnancy.
Analysis
Sample size calculation was not considered because of 
the exploratory design of this pilot study. It was estimated 
that five egg donors per group (with each participant being 
her own control) would be sufficient to assess the efficacy 
and safety of the two new protocols for COH. Continuous 
variables are expressed as the mean values ± standard 
deviation (SD), and categorical variables as frequencies and 
percentages. Differences in quantitative variables between 
the control group and the corresponding intervention groups 
(protocol A versus protocol B; protocol A versus protocol C) 
were analyzed with the Wilcoxon signed-rank test for paired 
samples, and differences in categorical variables with 
the McNemar’s test. Statistical significance was set at a 
P-value ,0.05. Analysis was performed with the Statistical 
Package for the Social Sciences (IBM Corporation, Armonk, 
NY, USA), version 15.0 for Windows.
Results
A total of 15 eligible egg donors were invited to partici-
pate in the study, although one woman refused to sign the 
informed consent. Therefore, 14 patients participated in this 
self-controlled clinical study. In the early luteal arm, two 
women were excluded. (For one participant, COH with the 
standard protocol was cancelled, and the other participant 
abandoned the study prior to the second stimulation for 
personal reasons). In the midfollicular arm, one participant 
abandoned the study for personal reasons. Therefore, six 
participants were included in the analysis of midfollicular 
GnRH intervention (protocol B) and five in the analysis of 
the early luteal GnRH intervention (protocol C). The flow 
chart of the study population is shown in Figure 2.
Baseline characteristics of the participants are shown in 
Table 1. There were no statistically significant differences in 
terms of age, BMI, and pretreatment serum levels of FSH or 
AFC across the study groups.
The numbers of mature oocytes retrieved were similar for 











Lost to follow-up: 1
(missing)
Analyzed: 5Analyzed: 6
Lost to follow-up: 2
(cancellation,
missing)
Figure 2 Flow chart of the study population.
Note: Each number represents the number of people in the category.











Age, years 25.8±3.7 25.6±3.8 26.0±4.0
BMI, kg/m2 23.4±3.5 22.6±2.6 24.1±4.1
Serum FSH, mIU/mL 6.9±1.3 7.1±1.5 6.8±1.3
AFC 11.5±2.6 12.8±3.6 10.6±1.4
Note: Values are expressed as the mean ± standard deviation.
Abbreviations: n, number; BMI, body mass index; FSH, follicle-stimulating 
hormone; AFC, antral follicle count.





the standard protocol (83.3% versus 50% in the midfollicular 
arm, and 40% versus 40% in the early luteal arm, respectively, 
as shown in Table 2).
No cases of ovarian hyperstimulation syndrome (OHSS) 
were recorded.
Discussion
The results of this exploratory pilot study, conducted for ethi-
cal reasons in egg donors rather than in cancer patients, show 
that COH can be initiated at a random date in the menstrual 
cycle when GnRH antagonists are used to achieve estradiol 
suppression. The number of mature oocytes retrieved when 
ganirelix was used in both midfollicular and early luteal 
phases was similar to that retrieved with the standard COH 
protocol, independent of whether ganirelix was given on 
day 10 or day 20 of the menstrual cycle.
The available evidence regarding the different emergency 
fertility preservation strategies for COH and their effective-
ness is sparse. In this regard, various case reports and series 
of short cases on random-start COH have been published 
with encouraging results.6,13,14 In the study by Sönmezer 
et al,6 random-start COH on three patients diagnosed with 
breast cancer commenced immediately on menstrual cycle 
days 11, 14, or 17 with the use of letrozole to suppress estra-
diol levels; between nine and 17 oocytes were harvested from 
each patient. Meanwhile, Ozkaya et al13 initiated random-
start COH on a patient, who was diagnosed with Hodgkin 
lymphoma, on day 11 of her menstrual cycle with the use 
of the GnRH antagonist ganirelix from day 1 of COH; from 
this patient, 17 mature oocytes were obtained. Similarly, 
in the study by Nayak and Wakim,14 a random-start GnRH 
antagonist cycle with cetrorelix from day 1 of COH was 
used on four patients, two of whom were on the 10th day of 
their menstrual cycles, one of whom was on the 17th day 
of her menstrual cycle, and one whose day of her menstrual 
cycle was unknown; between six and 30 mature oocytes were 
harvested from each of these patients. In addition, Kuang 
et al15 described how luteal phase ovarian stimulation with 
human menopausal gonadotropin and letrozole after spon-
taneous ovulation was also a feasible option for producing 
high-quality oocytes and embryos (11.2±7.2 oocytes were 
harvested from the human menopausal gonadotropin group, 
and 4.8±4.1 oocytes from the letrozole group); optimal 
pregnancy outcomes after embryo transfer were achieved.15 
However, because of the nature of these study designs, no 
control group was used to compare the results; hence, the 
applicability of these results must be interpreted in this 
context.
Findings from our trial indicate that the duration of an 
ovarian stimulation cycle for egg retrieval can be shorter com-
pared to that of the standard protocols of COH. According to 
the standard protocols, if a reproductive-age cancer patient 
is referred for emergency fertility preservation on day 10 of 
her menstrual cycle and has regular menses, clinicians should 
wait until day 2 of the following menstrual cycle to initiate 
COH (an approximately 20-day period). However, when the 
proposed GnRH antagonist ganirelix protocol was followed, 
ovarian stimulation was initiated 2.8±0.8 days after the mid-
follicular phase started and was finished in 9.8±0.8 days. 
Similar results were obtained when the GnRH antagonist 
was used during the early luteal phase; these results allowed 
clinicians to initiate COH 3.6±1.6 days after the phase 
started and proceed to oocyte retrieval after 10.6±2.1 days. 
Surprisingly, the implementation of this protocol entailed 














Total women 6 6 5 5
Total number of oocytes 24.8±13.0 19.2±11.1 0.141 17.0±7.9 18.4±10.6 0.892
 Mature oocytes (metaphase 2) 16.2±4.1 13.0±9.1 0.225 12.4±5.2 13.2±5.2 0.786
 Immature oocytes 8.6±10.6 6.2±8.5 0.066 4.6±4.6 5.2±5.5 0.686
 Fertilization rate 76.3% 75.9% 0.268 75.8% 78.1% 0.573
 Top-quality embryos 45.4% 46.2% 0.451 47.1% 46.5% 0.853
 Frozen embryos 4.3±2.8 4.1±2.1 0.278 3.9±1.9 4.6±2.3 0.342
Total rFSH dose, mIU/mL 1,680±445 1,595±300 0.500 1,966.7±559 1,837.5±580 0.753
Days on ganirelix 5.8±1.9 7.8±3.3 0.180 6.5±0.6 8.2±3.5 0.581
Days of stimulation 10.4±1.5 9.8±0.8 0.257 12.2±1.9 10.6±2.1 0.221
Clinical pregnancy rate, n (%) 3 (50) 6 (100) 2 (40) 3 (60)
Ongoing pregnancy rate, n (%) 3 (50) 5 (83.3) 2 (40) 2 (40)
Note: Data are expressed as the mean ± standard deviation unless otherwise stated.
Abbreviations: COH, controlled ovarian hyperstimulation; rFSH, recombinant follicle-stimulating hormone; n, number.





shorter time intervals than those observed in fertility 
preservation programs through oocyte cryopreservation via 
vitrification.16,17
Interestingly, results from this trial did not show differences 
in terms of the mean numbers of immature oocytes retrieved 
among participants who underwent either the midfollicular 
phase or the early luteal phase protocols when compared to the 
mean number of oocytes obtained during the standard COH 
protocol (6.2±8.5 versus 8.6±10.6 in the midfollicular arm, and 
5.2±5.5 versus 4.6±4.6 in the early luteal arm, respectively). 
The study showed no differences in either oocyte quality and 
maturation or pregnancy rates; this finding suggests that the 
fertility potential of the oocytes was not altered. Ongoing preg-
nancy rates were similar for the early luteal phase protocol and 
for the standard protocol (40% versus 40%, respectively). How-
ever, in the midfollicular arm, higher rates were observed with 
the midfollicular protocol compared to those with the standard 
protocol (83.3% versus 50%). However, these could be ran-
dom differences due to the small sample size. Nevertheless, 
in a study by Budak et al18 regarding the experience in oocyte 
donation cycles, the results showed an improvement in ongoing 
pregnancy rates, which increased from 31% to 44.3% over a 
period of 10 years.18 The latter results are consistent with the 
data obtained in our study.
The higher ovarian response obtained with the midfolli-
cular phase protocol than with the early luteal phase protocol 
could be explained by differences in the baseline AFC between 
the two groups. Interestingly, differences in terms of AFC in 
the baseline characteristics comparison were not statistically 
significant; however, it would be reasonable to consider that 
the small sample size could interfere with the accuracy of 
these results. AFC is a well known marker of ovarian response 
for controlled ovarian stimulation in conventional IVF and 
ICSI.19,20 Finally, an additional advantage of applying a GnRH 
antagonist cycle with a GnRH agonist trigger is to prevent 
OHSS, whose incidence is reduced significantly by this type 
of treatment; thereby, this approach constitutes a safe strategy 
for egg donors.10 None of our patients had OHSS, despite the 
large number of oocytes retrieved.
The main limitations of this study include the explor-
atory and pilot nature of the trial and the small sample size. 
However, this is the first trial to assess the efficacy and safety 
of two different random-start GnRH antagonist protocols in 
two different phases of the menstrual cycle. Results from 
this trial show that GnRH antagonists are an effective and 
safe strategy to initiate COH at a random date to achieve an 
ovarian response similar to that obtained with the standard 
COH protocol. This new approach of emergency fertility 
preservation overcomes the inconveniences of waiting for 
the menstrual period to initiate and responds to the urgent 
treatment needs of cancer patients. However, larger ran-
domized controlled studies are necessary to confirm these 
findings.
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